Introduction: The role of serum tumor markers in the modern management of advanced NSCLC remains poorly described.
Introduction
Many epithelial tumors express antigens detectable in the blood that are commonly called serum tumor markers.
1,2 Such markers have been investigated as screening tools, prognostic markers, and surrogate markers for disease response, recurrence, or progression. [3] [4] [5] [6] [7] [8] The spectrum of common serum tumor markers associated with advanced NSCLC has not been described in detail before. In addition, given that driver oncogenes are known to influence aspects of NSCLC behavior, we explored whether the expression of specific tumor markers varied by driver mutation status and how these markers changed during therapy and at progression. EGFR or KRAS mutation or an anaplastic lymphoma kinase gene (ALK) or ROS1-rearranged stage IV lung adenocarcinoma was performed to assess the characteristics and utility of serum tumor markers.
Patients had to have had at least one of four serum tumor markers, including carcinoembryonic antigen (CEA) (normal range 0-3 ng/mL), CA125 (normal range 0-35 U/mL), CA27.29 (normal range 0-35 U/mL), and/ or CA19.9 (normal range 0-40 U/mL) measured at baseline (defined as any time with known stage IV disease before or within 14 days of initiation of first-line platinum doublet chemotherapy for KRAS-mutant disease or a relevant tyrosine kinase inhibitor (TKI) associated with an objective response rate of greater than 40% for the EGFR, ALK, and ROS1 group). Patients with EGFR-, ALK-, and ROS1-positive tumors suitable for longitudinal assessment had serial tumor markers measured during therapy with a relevant TKI until progression. Imaging and laboratory collection times were not standardized.
Statistical Methods
For the statistical methods, see Supplementary Data 1.
Results

Patient Demographics
A total of 381 patients with stage IV oncogene-addicted NSCLC were initially identified. From these, 239 patients were excluded: 122 because they did not have recorded tumor marker levels; 76 without baseline levels within the relevant time period recorded; 17 (with EGFR, ROS1, or ALK positivity) because they were not treated with a TKI during the observation period, 22 who were treated with a TKI but did not have tumor markers measured, and two with no clinical information available, which left 142 for evaluation. Clinical and demographic characteristics for these patients are shown in Table 1 .
Pattern of Testing
Of the 142 patients, 97 (68%) had only one tumor marker tested, and in all cases it was CEA. Twenty-one patients had all four markers checked at baseline.
Frequency of Increased Level of Tumor Markers at Baseline
Of the 142 patients, 117 (82%) had at least one tumor marker increased above the upper limit of normal (Fig. 1) . The frequency of marker positivity increased with the number of markers assessed (78% for one marker, 88% and 86% for two and three markers, respectively, and 95% for all four markers). In contrast to CEA, CA125 and CA19.9, where there were no statistically significant differences in marker increase by oncogenic driver; the frequency of increase in CA27.29 level was significantly lower with KRAS than with the other drivers (p ¼ 0.016 [Fisher's exact test]) (Fig. 1B) . In the quadruple-tested subset ( Supplementary Fig. 1 ), three of the 21 patients (14%) had an increase in level of only a single tumor marker: two patients had an increase in their level of only CA125, and one patient had an increased level of CA 27.29. At baseline, 81% of patients had their levels of more than one tumor increased, and 24% had their levels of all four tumor markers increased at baseline.
Of those patients whose cancer was diagnosed at stage IV, 82% had an increase in CEA level, whereas patients whose cancer was initially diagnosed at stage I, II, or III had an increased level of CEA only (at the time of stage IV disease) in 50%, 50% and 52% of cases, respectively (p ¼ 0.002). No other variables assessed (smoking status, age at diagnosis, sex, number of metastases at diagnosis, or specific sites of metastasis at diagnosis of stage IV disease) were associated with an increase in CEA level.
Time to Nadir for Each Tumor Marker during Therapy
The median times to nadir (lowest level reached after the start of relevant treatment before disease progression) for the KRAS, ALK, ROS1, and EGFR groups are shown in Supplementary Fig. 2 .
Initial Increase in Tumor Marker with a Subsequent Decrease in Patients with EGFR Mutation or ALK or ROS1 Rearrangement during TKI Therapy
In all, 41 patients who had an oncogene-addicted lung cancer (EGFR, ALK, or ROS1) and were treated with a TKI had an increased CEA level at baseline had serum tumor markers measured within 4 weeks of starting treatment ( Supplementary Fig. 3 ). Of the 41 patients with EGFR mutation or ALK or ROS1 rearrangement, 24 (59%) demonstrated an initial increase in CEA level within the first 4 weeks of TKI therapy, with 58% of them having that level then fall below baseline.
Tumor Marker Increase from Nadir Values Depending on Site of Progression
In all, 53% of patients with an increased CEA level at baseline (25 of 47) had an increase in level of their tumor markers (by 10% from their nadir) when systemic or systemic and CNS progression developed. Only 22% of patients with increased tumor marker levels at baseline (two of nine) had an increase in their tumor markers (by 10% from their nadir) at development of CNS-only progression (Fig. 2) .
Lead Time from Tumor Marker Increase after Nadir to Radiographic Progression
The potential for rises in serum tumor markers during therapy after an initial nadir to introduce some lead time before radiographically defined progression are explored in Supplementary Data Set 2.
Discussion
Despite their noted association with other tumor types, CEA, CA125, CA19.9, and CA27.29 can all be increased in stage IV NSCLC (see Table 1 and Fig. 1 ). [1] [2] [3] [4] [5] [6] [7] [8] The highest rates of increase were with CA27.29 (86%) and the lowest were with CA19.9 (46%) (Figs. 1A and Supplementary Fig. 1 ). Most cancers (81%) express more than one marker, with 24% having levels of all four increased. However, some lung cancers expressed only one marker. Therefore, to maximize the chances of detecting an increase, the levels of all four should be checked at baseline to identify the relevant markers for that individual. Only the frequency of increase in CA27.29 level differed significantly by oncogene (lower in KRAS) (p ¼ 0.016); however, the absolute numbers within each oncogene/marker tested group were small and we cannot exclude any bias in selection for which markers to check.
In the CEA-tested data set there was no association between baseline increase and clinical features except stage at diagnosis, with 82% of patients whose cancer was diagnosed at stage IV having an increased level of CEA but only 50%, 50%, and 52% of those whose disease was initially diagnosed at stage I, II, or III, respectively, having an increased level of CEA at the time of stage IV disease (p ¼ 0.002), potentially reflecting an impact of disease burden at stage IV that is not captured by the other analyses. We were unable to control for several factors that could have affected baseline marker levels, including inflammation, hepatic/renal disorders, and conditions such as ovarian cysts. [1] [2] [3] [4] [5] [6] [7] [8] 10 However, longitudinally, as each patient acted as his or her own control, any impact of such conditions would be lessened. The presence of other occult cancers seems unlikely, as these were all fully staged cases.
Among EGFR-, ALK-, or ROS1-positive patients, repeat tumor marker sampling within the first 4 weeks of TKI therapy showed a decrease in 41%. However, 59% of these patients exhibited an initial increase, with marker levels later falling from this peak in 67% (to below the baseline levels in 58%) and with only 25% of those whose markers initially rose actually manifesting progression on their first scan (Supplementary Fig. 3 ). The initial rise appeared to be higher among those who subsequently progressed on their first scan (median 133% rise) than among those who did not (median 86% rise). The unreliability of markers within the first 4 weeks of therapy suggests either that they should not be checked or that these data inform both reassurance of the majority of patients with early increases and a commitment to explore their significance (particularly in those with greater proportional increases) with appropriately timed reimaging.
The median times to nadir during treatment did not appear to differ by the specific tumor marker or between those cases treated with TKIs or chemotherapy ( Supplementary Fig. 2) . Unfortunately, because of the nonstandardized frequency of sampling of these markers, the range around each of these medians is broad. had an increase in their tumor marker levels (by 10% from their nadir) when systemic or systemic and CNS progression occurred. Only 22% of patients with increased tumor marker levels at baseline (two of nine) had an increase in their tumor marker levels (by 10% from their nadir) when their CNS-only progression developed.
The exact change in tumor markers that should be considered "progression" remains uncertain. A 10% or greater increase from nadir preceded radiographic progression, with the median lead time ranging from 34 to 83 days (Supplementary Data Set 2). Whether these lead times would change if the frequency of tumor marker sampling/imaging were changed remains unknown. Among the 53% of those who had radiographic systemic or systemic and CNS progression, increases in CEA level of 10% or more occurred; however, such increases occurred in only 22% of cases of CNS-only progression (Fig. 2) . Thus, although tumor markers may inform the chances of progression during therapy, they cannot replace radiographic surveillance of either the body as a whole or especially the CNS. 11 These data support additional research looking at different proportional or absolute changes from nadir to better define tumor marker progression. [11] [12] [13] [14] As the management of oncogene-addicted NSCLC now includes the potential to use local ablative therapies for oligoprogression, tumor markers could be explored to see whether any lead time advantage will translate into a way of changing the proportion identified with a therapeutically tractable "early stage" of progression. 15 Our data need to be validated by a prospective evaluation in patients in whom marker levels are checked and imaging is performed at standardized intervals. Their use as an adjunct to decision making is worthy of further exploration to fully describe their relationship to disease activity and the optimal modern management of advanced NSCLC.
